This research is being done to test the safety and effectiveness of axicabtagene ciloleucel
(axi-cel), an anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy in treating
relapsed/refractory central nervous system (CNS) lymphoma, systemic lymphoma with concurrent
CNS lymphoma, or systemic lymphoma with a history of treated CNS lymphoma, and to better
understand what causes neurological toxicity following treatment with axi-cel.
The names of the study drug(s) involved in this study are:
- axicabtagene ciloleucel (axi-cel)
- ludarabine will be given with axicel to help axicel work more effectively
- cyclophosphamide will be given with axicel to help axicel work more effectively